GLP-1 receptor agonists × glycemic control

TrialDiabetes, obesity & metabolism2011

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes.

A Garber et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 2011

Not counted

Probably lowered glycemic control

−0.37−0.71 to −0.02

As reported

difference −0.37, 95% CI −0.71 to −0.02

Not counted

Probably lowered glycemic control

−0.55−0.88 to −0.21

As reported

difference −0.55, 95% CI −0.88 to −0.21

Not counted

Probably lowered glycemic control

−0.60−0.83 to −0.38

As reported

difference −0.6, 95% CI −0.83 to −0.38

Not counted

Probably lowered glycemic control

−0.31−0.54 to −0.08

As reported

difference −0.31, 95% CI −0.54 to −0.08

Four numbers in the abstract

the abstract, start to end

with liraglutide 1.2 mg (difference: -0.37, 95% CI: -0.71 to -0.02; p = 0.0376) and -1.1% with liraglutide 1.8 mg (difference: -0.55, 95% CI: -0.88 to -0.21; p =

were -0.3% with glimepiride versus -0.6% with liraglutide 1.2 mg (difference: -0.31, 95% CI: -0.54 to -0.08; p =

← favours treatmentfavours comparator →
could be chance
Glycemic control
−0.37−0.71 to −0.02
Glycemic control
−0.55−0.88 to −0.21
Glycemic control
−0.6−0.83 to −0.38
Glycemic control
−0.31−0.54 to −0.08
GLP-1 receptor agonistsSulfonylureas & glinidesGlycemic control
1 / 3

73 papers cite itlatest 60 shown

2011
2012
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 21205128